Drugs / Hib-TT
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00342628 Comparator | Jul 2006 → Apr 2008 | typhoid fever | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 3 | NCT02139228 Comparator | Nov → Dec 2014 | haemophilus infectious disease | Novartis Vaccines | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hib-TT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02139228 ↗ |
| Known as | ActHib | “Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP...” NCT00342628 ↗ |
| Modality | Vaccine | “Hemophilus influenzae type b-tetanus toxoid conjugate vaccine” NCT00342628 ↗ |